Matches in Nanopublications for { ?s ?p "[HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- assertion description "[HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP295352.RA_iGFD1sw7z2qrJ_9n96dr6kh6vuN2q_3oV0UWsFSS9Q130_assertion description "[HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP295352.RA_iGFD1sw7z2qrJ_9n96dr6kh6vuN2q_3oV0UWsFSS9Q130_provenance.
- NP505993.RAAp66v7oggR9v36ABJ4W5r-WT3KH8AtM0LGq6A8N5Q1M130_assertion description "[HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP505993.RAAp66v7oggR9v36ABJ4W5r-WT3KH8AtM0LGq6A8N5Q1M130_provenance.
- NP428661.RAg08kXoI5C0titDy4o-JV9ngaUcDRYHY-TwqZ0BYCuXg130_assertion description "[HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP428661.RAg08kXoI5C0titDy4o-JV9ngaUcDRYHY-TwqZ0BYCuXg130_provenance.
- NP505982.RAbG7MH7AjzhuFOb5M5gGbpVIEnKpW8Cd2gF6WVSrzcyE130_assertion description "[HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP505982.RAbG7MH7AjzhuFOb5M5gGbpVIEnKpW8Cd2gF6WVSrzcyE130_provenance.
- NP428735.RAELreKur4JLE3rCbmlWq_nkTSSTdGtl1p6m9ti1ThJRE130_assertion description "[HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP428735.RAELreKur4JLE3rCbmlWq_nkTSSTdGtl1p6m9ti1ThJRE130_provenance.